Technical Analysis for COCP - Cocrystal Pharma, Inc.

Grade Last Price % Change Price Change
D 1.6101 1.91% 0.03
COCP closed up 0.64 percent on Monday, March 1, 2021, on 33 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical COCP trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.91%
Oversold Stochastic Weakness 1.91%
Stochastic Reached Oversold Weakness 2.55%
Wide Bands Range Expansion 2.55%
Lower Bollinger Band Touch Weakness 2.55%
Oversold Stochastic Weakness 2.55%
50 DMA Resistance Bearish -1.82%
MACD Bearish Centerline Cross Bearish -1.82%
Wide Bands Range Expansion -1.82%
50 DMA Resistance Bearish -6.39%
Older End-of-Day Signals for COCP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 2 hours ago
Up 2% about 2 hours ago
Up 1% about 2 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Down 3% about 20 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cocrystal Pharma, Inc. Description

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Influenza Coronavirus Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries

Is COCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.04
52 Week Low 0.6
Average Volume 3,345,731
200-Day Moving Average 1.40
50-Day Moving Average 1.73
20-Day Moving Average 1.90
10-Day Moving Average 1.80
Average True Range 0.19
ADX 21.95
+DI 17.38
-DI 26.35
Chandelier Exit (Long, 3 ATRs ) 1.71
Chandelier Exit (Short, 3 ATRs ) 2.08
Upper Bollinger Band 2.28
Lower Bollinger Band 1.51
Percent B (%b) 0.09
BandWidth 40.71
MACD Line -0.04
MACD Signal Line 0.03
MACD Histogram -0.0662
Fundamentals Value
Market Cap 108.33 Million
Num Shares 68.6 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -1.08
Price-to-Sales 39.86
Price-to-Book 2.24
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.84
Resistance 3 (R3) 1.85 1.77 1.79
Resistance 2 (R2) 1.77 1.70 1.76 1.78
Resistance 1 (R1) 1.67 1.66 1.64 1.67 1.77
Pivot Point 1.60 1.60 1.58 1.59 1.60
Support 1 (S1) 1.50 1.53 1.46 1.49 1.39
Support 2 (S2) 1.43 1.49 1.42 1.38
Support 3 (S3) 1.33 1.43 1.37
Support 4 (S4) 1.32